[Ip-health] At $2.1M, Novartis gene therapy will be world’s most expensive drug

Ellen 't Hoen ellenthoen at medicineslawandpolicy.net
Fri May 24 22:20:57 PDT 2019


Dear IP-Health readers,

The new gene therapy for children under 2 years of age with spinal muscular atrophy, approved by the FDA and sold by Novartis under the brand name Zolgensma, will be priced at $2.1 million. 

The article mentions that: “Novartis defends its pricing decision, calling the treatment “highly cost effective” and “fair and reasonable” given the benefit demonstrating in clinical trials. Novartis pointed out that chronic injections of Spinraza cost more than $4 million over five years. “

Spinrasa used to be the most expensive product until the approval of Zolgensma.

https://www.statnews.com/2019/05/24/hold-novartis-zolgensma-approval/

Relevant piece of news for the discussion on the need for greater price and cost transparency currently taking place at the World Health Assembly in Geneva. 

————————————————————
Ellen ‘t Hoen LLM, PhD | Medicines Law & Policy
www.medicineslawandpolicy.org
E-mail: ellenthoen at medicineslawandpolicy.net
Twitter: @ellenthoen



More information about the Ip-health mailing list